SCHEMBL13462056

SCHEMBL13462056

OC(O)Sc1ccc(CS)cc1

nearest known ligand 0.41

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 6/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL636180 0.72 IDO1 (0.50) IDO1
SCHEMBL127369 0.71 IDO1 (0.69) IDO1
SCHEMBL2201278 0.69 MAOA (0.37) IDO1
SCHEMBL1145845 0.69 IDO1 (0.52) IDO1
SCHEMBL11428396 0.65 SLC6A4 (0.53) IDO1
SCHEMBL6073335 0.64 IDO1 (0.52) IDO1
SCHEMBL494668 0.64 — —
SCHEMBL19914064 0.64 SLC6A4 (0.47) IDO1
SCHEMBL635341 0.63 IDO1 (0.58) IDO1
SCHEMBL441726 0.63 IDO1 (0.58) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP IDO1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback